ログイン
言語:

WEKO3

  • トップ
  • ランキング
To

Field does not validate

To

Field does not validate

To
lat lon distance


インデックスリンク

インデックスツリー

  • RootNode

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 0 資料タイプ別
  2. 02 学位論文
  1. 250 大学院医歯学総合研究科(医)
  2. 60 博士学位論文
  3. 10 博士学位論文

The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3

http://hdl.handle.net/10191/00051954
http://hdl.handle.net/10191/00051954
7e9a13bd-9ede-434b-ab86-b0fd13f270c3
名前 / ファイル ライセンス アクション
r2nmk963.pdf 本文 (1.5 MB)
r2nmk963_a.pdf 要旨 (458.1 kB)
Item type 学位論文 / Thesis or Dissertation(1)
公開日 2020-11-12
タイトル
タイトル The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3
言語
言語 eng
キーワード
主題Scheme Other
主題 Low-dose NAC
キーワード
主題Scheme Other
主題 MMP-3
キーワード
主題Scheme Other
主題 JNK pathway
キーワード
主題Scheme Other
主題 MH7A
キーワード
主題Scheme Other
主題 RA-FLS
資源タイプ
資源 http://purl.org/coar/resource_type/c_46ec
タイプ thesis
その他のタイトル
その他のタイトル JNK pathwayはMMP-3抑制を通して関節リウマチ治療における新たな標的になる
著者 Kanai, Tomotake

× Kanai, Tomotake

WEKO 178214

Kanai, Tomotake

Search repository
著者別名
識別子Scheme WEKO
識別子 178215
姓名 金井, 朋毅
抄録
内容記述タイプ Abstract
内容記述 Background and aim: The pathophysiology of rheumatoid arthritis (RA) is characterized by excess production of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL6) by neutrophils and macrophages in synovium. Additionally, these cytokines promote the production of reactive oxygen species (ROS), and increased production of matrix metalloproteinases (MMPs), including MMP-3, in synoviocytes that result in joint destruction. There is limited information on how proteolytic enzymes such as MMP3 can be regulated. We evaluated the effect of the antioxidant N-acetylcysteine (NAC) on RA and identified the relationship between the c-Jun N terminal kinase (JNK) pathway and MMP-3. We hypothesized that elucidating this relationship would lead to novel therapeutic approaches to RA treatment and management. Methods: We investigated the effect of administering a low dose (1000 μM or less) of an antioxidant (NAC) to human rheumatoid fibroblast-like synoviocytes (MH7A cells). We also investigated the response of antioxidant genes such as nuclear factor erythroid -derived 2-related factor 2 (Nrf2) and Sequestosome 1 (p62). The influence of MMP-3 expression on the JNK pathway leading to joint destruction and the mechanisms underlying this relationship were investigated through primary dispersion culture cells collected from the synovial membranes of RA patients, consisting of rheumatoid arthritis-fibroblast-like synoviocytes (RA-FLS). Results: Low-dose NAC (1000 μM) increased the expression of Nrf2 and phospho-p62 in MH7A cells, activating antioxidant genes, suppressing the expression of MMP-3, and inhibiting the phosphorylation of JNK. ROS, MMP-3 expression, and IL-6 was suppressed by administering 30 μM of SP600125 (a JNK inhibitor) in MH7A cells. Furthermore, the administration of SP600125 (30 μM) to RA-FLS suppressed MMP-3. Conclusions: We demonstrated the existence of an MMP-3 suppression mechanism that utilizes the JNK pathway in RA-FLS. We consider that the JNK pathway could be a target for future RA therapies.
内容記述
内容記述タイプ Other
内容記述 Journal of Orthopaedic Surgery and Research. 2020, 15, 87.
DOI
識別子タイプ DOI
関連識別子 info:doi/10.1186/s13018-020-01595-9
権利
権利情報 【○!C】 The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
著者版フラグ
値 ETD
学位名
学位名 博士(医学)
学位授与機関
学位授与機関名 新潟大学
学位授与年月日
学位授与年月日 2020-09-23
学位授与番号
学位授与番号 13101甲第4793号
学位記番号
内容記述タイプ Other
内容記述 新大院博(医)甲第963号
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 07:50:21.060554
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3